Previous Close | 0.5200 |
Open | 0.5500 |
Bid | 0.5100 x N/A |
Ask | 0.5600 x N/A |
Day's Range | 0.5100 - 0.5700 |
52 Week Range | 0.4800 - 2.8500 |
Volume | |
Avg. Volume | 25,403 |
Market Cap | 24.014M |
Beta (5Y Monthly) | 1.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2600 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Maxime Parisotto has joined the Company as Chief Scientific Officer, Director of Science and Business Developmen
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, announces that it has closed its offering of unsecured convertible debentures (the "New Debentures") for aggregate gross proceeds of CAD$1,476,0